{"success":true,"data":{"pressRelease":{"id":"164099","rtpr_id":"nGNX2MkFqD-20261008","ticker":"CNSY","exchange":"NASDAQ","all_tickers":["CNSY"],"title":"Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests","author":"Globe Newswire","published_at":"2026-10-08T11:30:00.223Z","article_body":"First CNSide payer agreement to include CNSide’s new CSF Molecular Profile\ntests alongside tumor cell enumeration\n\nExpands CNSide contracted payer access to approximately 164 million covered\nlives\n\nHOUSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a\nwholly-owned subsidiary of Cerenome, Inc.\n(https://www.globenewswire.com/Tracker?data=oomzqNbXD5CQ_Yn_eM-1aXUHkjvwhNZ4Cf_MKgxgewbLoVUXDzOTbo5AFxoHq97LTp3aI6rY_eZmHWOgHkpShBoK52hyULo1odLgIaeZmTY=) (Nasdaq: CNSY\n(https://www.globenewswire.com/Tracker?data=u4paMs3FduxfI3QdWotAcwVJ2z6xcKyHjLTouQi70EZQAgxPYwYseD9mAlZH-2O4BH8TlkSnpJsXQNO2Vn7m7k6bv-b_50w60eeeeOqqcicGjCaoug8asxJCHSVrn-Ys))\n(“Cerenome” or the “Company”), announced today that it has entered\ninto an in-network ancillary provider agreement with Blue Cross and Blue\nShield of Florida, Inc. (Florida Blue), effective October 1, 2026.\n\nThe agreement establishes contracted reimbursement for the CNSide(®)\nCerebrospinal Fluid (CSF) Tumor Cell Enumeration test as well as CNSide(®)\nCSF Molecular Profile tests for solid tumors and hematologic malignancies\ninvolving the central nervous system. It is the first CNSide payer agreement\nto include both tumor cell enumeration and molecular profiling.\n\nThe Florida Blue agreement adds approximately 6 million covered lives to\nCNSide’s contracted payer footprint. Combined with previously announced\npayer agreements, CNSide has now established in-network agreements\nrepresenting approximately 164 million commercial and Medicare Advantage\ncovered lives, reflecting continued execution of the Company’s national\nreimbursement strategy.\n\n“This agreement with Florida Blue represents an important milestone in\nCNSide’s commercial trajectory,” said Marc Hedrick, M.D., Cerenome’s\nPresident and Chief Executive Officer. “By expanding contracted\nreimbursement to both cellular and molecular CSF testing, we are advancing\nCNSide as a broader CSF diagnostics platform for CNS oncology, combining\ntumor-cell analysis and molecular profiling to better characterize and monitor\ncancers involving the central nervous system.”\n\nThe Florida Blue agreement expands the scope of CNSide’s contracted\nreimbursement beyond tumor cell detection in leptomeningeal metastases to\ninclude molecular profiling of CNS malignancies. CNSide(®) CSF Molecular\nProfile - Solid Tumor provides DNA and RNA molecular profiling of CSF for\npatients with suspected or confirmed primary CNS tumors or solid tumors\nmetastatic to the CNS, including brain and leptomeningeal metastases.\nCNSide(®) CSF Molecular Profile - Hematologic Malignancy provides DNA and RNA\nmolecular profiling of CSF for patients with suspected or confirmed\nhematologic malignancies involving the CNS. CNSide(®) CSF Molecular Profile\ntests are now commercially available through CNSide.\n\nThe DNA and RNA CSF molecular profiling approach underlying CNSide(®) CSF\nMolecular Profile was recently evaluated in a peer-reviewed, real-world study\nof 1,391 evaluable CSF specimens from patients being evaluated for primary CNS\ntumors, metastatic CNS disease, and hematologic malignancies involving the\nCNS, published in The Journal of Liquid Biopsy.\n\nThe clinical utility of CNSide CSF tumor cell analysis in leptomeningeal\nmetastases is supported by evaluation in 12 peer-reviewed publications,\nprospective multicenter evidence from the FORESEE clinical study, and\nreal-world clinical experience. Since 2020, more than 11,000 CNSide(®) tests\nhave been performed at more than 120 U.S. cancer institutions, supporting\nclinical decision-making across academic and community oncology practices\nnationwide. \n\nAbout Florida Blue\nDriven by its mission of helping people and communities achieve better health,\nFlorida Blue is the leading health insurer in Florida, and part of GuideWell,\na not-for-profit health solutions company.  Florida Blue offers a range of\nhealth plans and personalized care programs for individuals, families,\nbusinesses of all sizes, and Medicare beneficiaries. For over 80 years, the\norganization has been member centric and committed to making health care as\naccessible and affordable as possible. Serving more than six million members\nacross all 67 Florida counties, Florida Blue has more than 7,000 employees, is\nheadquartered in Jacksonville, Fla., is owned by its policyholders, and is an\nindependent licensee of the Blue Cross Blue Shield Association.\n\nAbout CNSide Diagnostics, LLC \nCNSide Diagnostics, LLC is a wholly owned subsidiary of Cerenome, Inc. that\ndevelops and commercializes cerebrospinal fluid (CSF)-based diagnostic tests\nfor cancers involving the central nervous system. The CNSide(®) CSF\ndiagnostics platform combines cellular analysis, biomarker characterization,\nand molecular profiling to support the detection, characterization, and\nlongitudinal assessment of CNS malignancies. CNSide currently offers\nCNSide(®) CSF Tumor Cell Enumeration for patients with suspected or confirmed\nleptomeningeal metastases and plans to launch CNSide(®) CSF Molecular Profile\ntests for molecular characterization of primary CNS tumors, solid tumors\nmetastatic to the CNS, and hematologic malignancies involving the CNS in\nOctober 2026. For more information, visit https://www.cnside-dx.com\n\nAbout Cerenome\nCerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated\nplatform that combines precision diagnostics, targeted therapeutics, and\nartificial intelligence to improve outcomes for patients with central nervous\nsystem cancers. The CNSide(®) CSF diagnostics platform combines cellular and\nmolecular testing to support the detection, characterization, and longitudinal\nassessment of cancers involving the CNS. Its lead therapeutic platform,\nREYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials\nfor leptomeningeal metastases, recurrent glioblastoma, and pediatric brain\ncancers. The data & artificial intelligence platform is designed to integrate\ndiagnostic, molecular, imaging, and clinical data into actionable insights\nthat support precision oncology and therapeutic innovation. By integrating\ncommercial diagnostics, targeted therapeutics, proprietary longitudinal data,\nand artificial intelligence within a single organization, Cerenome is building\na differentiated CNS oncology platform designed to improve patient care while\ncreating long-term shareholder value. For more information, visit\nhttps://www.cerenome.com. \n\nForward-Looking Statements\nThis press release contains statements that may be deemed “forward-looking\nstatements” within the meaning of U.S. securities laws, including statements\nregarding clinical trials, expected operations and upcoming developments. All\nstatements in this press release other than statements of historical fact are\nforward-looking statements. These forward-looking statements may be identified\nby future verbs, as well as terms such as “expect,” “potential,”\n“anticipating,” “planning” and similar expressions or the negatives\nthereof. Such statements are based upon certain assumptions and assessments\nmade by management in light of their experience and their perception of\nhistorical trends, current conditions, expected future developments and other\nfactors they believe to be appropriate. These statements include, without\nlimitation, statements regarding the potential market for the CNSide CSF\nAssay, the timing in which the CNSide CSF Assay is commercially launched and\ncommercialization is expanded, revenue and corporate profitability\nexpectations including support reimbursements and payments for the CNSide CSF\nAssay, the development and utility of the CNSide CSF Assay and expectations as\nto the Company’s future performance, including the next steps in developing\nthe Company’s product candidates.\n\nInvestor Contact\nCORE IR\nIR@cerenome.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/50840ea8-0a62-4ebf-9451-396435061f07)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2MkFqD-20261008","title":"Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests","author":"Globe Newswire","ticker":"CNSY","created":"2026-10-08T11:30:00.223Z","tickers":["CNSY"],"exchange":"NASDAQ","article_body":"First CNSide payer agreement to include CNSide’s new CSF Molecular Profile\ntests alongside tumor cell enumeration\n\nExpands CNSide contracted payer access to approximately 164 million covered\nlives\n\nHOUSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a\nwholly-owned subsidiary of Cerenome, Inc.\n(https://www.globenewswire.com/Tracker?data=oomzqNbXD5CQ_Yn_eM-1aXUHkjvwhNZ4Cf_MKgxgewbLoVUXDzOTbo5AFxoHq97LTp3aI6rY_eZmHWOgHkpShBoK52hyULo1odLgIaeZmTY=) (Nasdaq: CNSY\n(https://www.globenewswire.com/Tracker?data=u4paMs3FduxfI3QdWotAcwVJ2z6xcKyHjLTouQi70EZQAgxPYwYseD9mAlZH-2O4BH8TlkSnpJsXQNO2Vn7m7k6bv-b_50w60eeeeOqqcicGjCaoug8asxJCHSVrn-Ys))\n(“Cerenome” or the “Company”), announced today that it has entered\ninto an in-network ancillary provider agreement with Blue Cross and Blue\nShield of Florida, Inc. (Florida Blue), effective October 1, 2026.\n\nThe agreement establishes contracted reimbursement for the CNSide(®)\nCerebrospinal Fluid (CSF) Tumor Cell Enumeration test as well as CNSide(®)\nCSF Molecular Profile tests for solid tumors and hematologic malignancies\ninvolving the central nervous system. It is the first CNSide payer agreement\nto include both tumor cell enumeration and molecular profiling.\n\nThe Florida Blue agreement adds approximately 6 million covered lives to\nCNSide’s contracted payer footprint. Combined with previously announced\npayer agreements, CNSide has now established in-network agreements\nrepresenting approximately 164 million commercial and Medicare Advantage\ncovered lives, reflecting continued execution of the Company’s national\nreimbursement strategy.\n\n“This agreement with Florida Blue represents an important milestone in\nCNSide’s commercial trajectory,” said Marc Hedrick, M.D., Cerenome’s\nPresident and Chief Executive Officer. “By expanding contracted\nreimbursement to both cellular and molecular CSF testing, we are advancing\nCNSide as a broader CSF diagnostics platform for CNS oncology, combining\ntumor-cell analysis and molecular profiling to better characterize and monitor\ncancers involving the central nervous system.”\n\nThe Florida Blue agreement expands the scope of CNSide’s contracted\nreimbursement beyond tumor cell detection in leptomeningeal metastases to\ninclude molecular profiling of CNS malignancies. CNSide(®) CSF Molecular\nProfile - Solid Tumor provides DNA and RNA molecular profiling of CSF for\npatients with suspected or confirmed primary CNS tumors or solid tumors\nmetastatic to the CNS, including brain and leptomeningeal metastases.\nCNSide(®) CSF Molecular Profile - Hematologic Malignancy provides DNA and RNA\nmolecular profiling of CSF for patients with suspected or confirmed\nhematologic malignancies involving the CNS. CNSide(®) CSF Molecular Profile\ntests are now commercially available through CNSide.\n\nThe DNA and RNA CSF molecular profiling approach underlying CNSide(®) CSF\nMolecular Profile was recently evaluated in a peer-reviewed, real-world study\nof 1,391 evaluable CSF specimens from patients being evaluated for primary CNS\ntumors, metastatic CNS disease, and hematologic malignancies involving the\nCNS, published in The Journal of Liquid Biopsy.\n\nThe clinical utility of CNSide CSF tumor cell analysis in leptomeningeal\nmetastases is supported by evaluation in 12 peer-reviewed publications,\nprospective multicenter evidence from the FORESEE clinical study, and\nreal-world clinical experience. Since 2020, more than 11,000 CNSide(®) tests\nhave been performed at more than 120 U.S. cancer institutions, supporting\nclinical decision-making across academic and community oncology practices\nnationwide. \n\nAbout Florida Blue\nDriven by its mission of helping people and communities achieve better health,\nFlorida Blue is the leading health insurer in Florida, and part of GuideWell,\na not-for-profit health solutions company.  Florida Blue offers a range of\nhealth plans and personalized care programs for individuals, families,\nbusinesses of all sizes, and Medicare beneficiaries. For over 80 years, the\norganization has been member centric and committed to making health care as\naccessible and affordable as possible. Serving more than six million members\nacross all 67 Florida counties, Florida Blue has more than 7,000 employees, is\nheadquartered in Jacksonville, Fla., is owned by its policyholders, and is an\nindependent licensee of the Blue Cross Blue Shield Association.\n\nAbout CNSide Diagnostics, LLC \nCNSide Diagnostics, LLC is a wholly owned subsidiary of Cerenome, Inc. that\ndevelops and commercializes cerebrospinal fluid (CSF)-based diagnostic tests\nfor cancers involving the central nervous system. The CNSide(®) CSF\ndiagnostics platform combines cellular analysis, biomarker characterization,\nand molecular profiling to support the detection, characterization, and\nlongitudinal assessment of CNS malignancies. CNSide currently offers\nCNSide(®) CSF Tumor Cell Enumeration for patients with suspected or confirmed\nleptomeningeal metastases and plans to launch CNSide(®) CSF Molecular Profile\ntests for molecular characterization of primary CNS tumors, solid tumors\nmetastatic to the CNS, and hematologic malignancies involving the CNS in\nOctober 2026. For more information, visit https://www.cnside-dx.com\n\nAbout Cerenome\nCerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated\nplatform that combines precision diagnostics, targeted therapeutics, and\nartificial intelligence to improve outcomes for patients with central nervous\nsystem cancers. The CNSide(®) CSF diagnostics platform combines cellular and\nmolecular testing to support the detection, characterization, and longitudinal\nassessment of cancers involving the CNS. Its lead therapeutic platform,\nREYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials\nfor leptomeningeal metastases, recurrent glioblastoma, and pediatric brain\ncancers. The data & artificial intelligence platform is designed to integrate\ndiagnostic, molecular, imaging, and clinical data into actionable insights\nthat support precision oncology and therapeutic innovation. By integrating\ncommercial diagnostics, targeted therapeutics, proprietary longitudinal data,\nand artificial intelligence within a single organization, Cerenome is building\na differentiated CNS oncology platform designed to improve patient care while\ncreating long-term shareholder value. For more information, visit\nhttps://www.cerenome.com. \n\nForward-Looking Statements\nThis press release contains statements that may be deemed “forward-looking\nstatements” within the meaning of U.S. securities laws, including statements\nregarding clinical trials, expected operations and upcoming developments. All\nstatements in this press release other than statements of historical fact are\nforward-looking statements. These forward-looking statements may be identified\nby future verbs, as well as terms such as “expect,” “potential,”\n“anticipating,” “planning” and similar expressions or the negatives\nthereof. Such statements are based upon certain assumptions and assessments\nmade by management in light of their experience and their perception of\nhistorical trends, current conditions, expected future developments and other\nfactors they believe to be appropriate. These statements include, without\nlimitation, statements regarding the potential market for the CNSide CSF\nAssay, the timing in which the CNSide CSF Assay is commercially launched and\ncommercialization is expanded, revenue and corporate profitability\nexpectations including support reimbursements and payments for the CNSide CSF\nAssay, the development and utility of the CNSide CSF Assay and expectations as\nto the Company’s future performance, including the next steps in developing\nthe Company’s product candidates.\n\nInvestor Contact\nCORE IR\nIR@cerenome.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/50840ea8-0a62-4ebf-9451-396435061f07)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-08T11:30:00.261927669Z","server_sent_at_ms":1791459000261},"received_at":"2026-10-08T11:30:00.379Z","source_url":null},"analysis":{"id":"152537","press_release_id":"164099","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":[],"eventType":"partnership","narrative":"Cerenome's subsidiary CNSide Diagnostics signed an in-network ancillary provider agreement with Florida Blue, effective October 1, 2026.\n\nIt is the first CNSide payer agreement to cover both the CSF Tumor Cell Enumeration test and the new CSF Molecular Profile tests, adding roughly 6 million covered lives and bringing total contracted access to approximately 164 million lives.\n\nThe deal supports CNSide's transition into a broader CSF diagnostics platform for CNS oncology, with the Molecular Profile tests commercially available and launching in October 2026.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"First dual-coverage CNSide payer deal expands reimbursement to ~164M covered lives, de-risking the molecular profile launch."},"keyFigures":{"customDimensions":{"covered_lives_added":"approximately 6 million","covered_lives_total":"approximately 164 million commercial and Medicare Advantage covered lives"}},"quotedText":"This agreement with Florida Blue represents an important milestone in CNSide's commercial trajectory","namedEntities":{"people":[{"name":"Marc Hedrick, M.D.","role":"President and CEO of Cerenome"}],"products":["CNSide CSF Tumor Cell Enumeration","CNSide CSF Molecular Profile - Solid Tumor","CNSide CSF Molecular Profile - Hematologic Malignancy","REYOBIQ (rhenium Re186 obisbemeda)"],"companies":[{"name":"Cerenome, Inc.","ticker":"CNSY","relationship":"filer (parent of CNSide Diagnostics)"},{"name":"CNSide Diagnostics, LLC","relationship":"wholly-owned subsidiary"},{"name":"Blue Cross and Blue Shield of Florida, Inc. (Florida Blue)","relationship":"payer partner"},{"name":"GuideWell","relationship":"parent of Florida Blue"},{"name":"CORE IR","relationship":"investor relations"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"First in-network payer agreement covering both CNSide tumor cell enumeration and new molecular profile tests, adding ~6 million covered lives and expanding contracted access to ~164 million lives. Meaningful commercial reimbursement progress for a small-cap diagnostics company, but not a binary or market-moving event."},"tickerRelevance":{"others":[],"primary":"CNSY"},"globalImportance":30,"audienceRelevance":22,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"payer-reimbursement-expansion","commercialMilestone":true,"householdBrandBoost":false}},"event_type":"partnership","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":3,"narrative":"Cerenome's subsidiary CNSide Diagnostics signed an in-network ancillary provider agreement with Florida Blue, effective October 1, 2026.\n\nIt is the first CNSide payer agreement to cover both the CSF Tumor Cell Enumeration test and the new CSF Molecular Profile tests, adding roughly 6 million covered lives and bringing total contracted access to approximately 164 million lives.\n\nThe deal supports CNSide's transition into a broader CSF diagnostics platform for CNS oncology, with the Molecular Profile tests commercially available and launching in October 2026.","key_figures":{"customDimensions":{"covered_lives_added":"approximately 6 million","covered_lives_total":"approximately 164 million commercial and Medicare Advantage covered lives"}},"named_entities":{"people":[{"name":"Marc Hedrick, M.D.","role":"President and CEO of Cerenome"}],"products":["CNSide CSF Tumor Cell Enumeration","CNSide CSF Molecular Profile - Solid Tumor","CNSide CSF Molecular Profile - Hematologic Malignancy","REYOBIQ (rhenium Re186 obisbemeda)"],"companies":[{"name":"Cerenome, Inc.","ticker":"CNSY","relationship":"filer (parent of CNSide Diagnostics)"},{"name":"CNSide Diagnostics, LLC","relationship":"wholly-owned subsidiary"},{"name":"Blue Cross and Blue Shield of Florida, Inc. (Florida Blue)","relationship":"payer partner"},{"name":"GuideWell","relationship":"parent of Florida Blue"},{"name":"CORE IR","relationship":"investor relations"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T11:30:07.469Z","global_importance":30,"audience_relevance":22,"importance_components":{"tickerTier":"small-cap","eventGravity":"payer-reimbursement-expansion","commercialMilestone":true,"householdBrandBoost":false}},"durationMs":7043,"modelName":"glm-5.3-flashx"}}